CMVLF
Price:
$3.47
Market Cap:
$221.59M
Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two principal divisions: Therapeutics and Plants. Its robust development pipeline includes several crucial product candidates. Notable among these is UCART19, an allogeneic T-cell treatment designed for CD19-expressing blood cancers like acute lymphoblastic leukemia. They are also progressing ALLO-501 and ALLO-501A, aimed at tackling relapsed/refractory diff...[Read more]
Industry
Biotechnology
IPO Date
2014-07-01
Stock Exchange
OTC
Ticker
CMVLF
According to Cellectis S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -5.18. This represents a change of -119.48% compared to the average of 26.59 of the last 4 quarters.
The mean historical PE Ratio of Cellectis S.A. over the last ten years is -7.26. The current -5.18 PE Ratio has changed 7.03% with respect to the historical average. Over the past ten years (40 quarters), CMVLF's PE Ratio was at its highest in in the September 2025 quarter at 117.34. The PE Ratio was at its lowest in in the June 2018 quarter at -42.26.
Average
-7.26
Median
-7.64
Minimum
-17.43
Maximum
-0.98
Discovering the peaks and valleys of Cellectis S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 181.10%
Maximum Annual PE Ratio = -0.98
Minimum Annual Increase = -79.60%
Minimum Annual PE Ratio = -17.43
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -7.05 | 71.19% |
| 2024 | -4.12 | 181.10% |
| 2023 | -1.46 | 49.48% |
| 2022 | -0.98 | -77.67% |
| 2021 | -4.39 | -74.82% |
| 2020 | -17.43 | 111.98% |
| 2019 | -8.22 | -8.05% |
| 2018 | -8.94 | -15.52% |
| 2017 | -10.58 | 12.37% |
| 2016 | -9.42 | -79.60% |
The current PE Ratio of Cellectis S.A. (CMVLF) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.21
5-year avg
-3.60
10-year avg
-7.26
Cellectis S.A.’s PE Ratio is less than Immutep Limited (-0.92), less than Transgene S.A. (-2.89), less than Frontage Holdings Corporation (40.60), greater than CytoDyn Inc. (-8.44), less than Hansa Biopharma AB (publ) (-4.11), less than Silence Therapeutics plc (-1.60), greater than Northwest Biotherapeutics, Inc. (-6.23), less than Probi AB (publ) (235.75), less than Clinuvel Pharmaceuticals Limited (15.85), greater than Healios K.K. (-10.67),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.92 | $73.69M | |
| -2.89 | $122.57M | |
| 40.60 | $223.05M | |
| -8.44 | $369.83M | |
| -4.11 | $245.80M | |
| -1.60 | $313.17M | |
| -6.23 | $312.23M | |
| 235.75 | $286.93M | |
| 15.85 | $307.51M | |
| -10.67 | $193.79M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cellectis S.A.'s PE Ratio?
How is the PE Ratio calculated for Cellectis S.A. (CMVLF)?
What is the highest PE Ratio for Cellectis S.A. (CMVLF)?
What is the 3-year average PE Ratio for Cellectis S.A. (CMVLF)?
What is the 5-year average PE Ratio for Cellectis S.A. (CMVLF)?
How does the current PE Ratio for Cellectis S.A. (CMVLF) compare to its historical average?